### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroup C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and chlorothiazide, chlortalidone and indapamide (for amlodipine), be specified as therapeutic alternatives under the square box listing for telmisartan + hydrochlorothiazide on the EML.